Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives Consensus Rating of “Buy” from Analysts
Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) has earned a consensus rating of “Buy” from the seven ratings firms that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price […]
Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) has earned a consensus rating of “Buy” from the seven ratings firms that are covering the firm, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price […]
